Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Serotonin agonists can reduce glutamate-induced excitotoxicity in cerebral ischemia. The potent 5-HT1A agonist BAY × 3702, or repinotan, has reduced cortical infarct volume in pre-clinical models even when given 5 hours after injury. Early clinical trials showed that the drug was safe, and displayed primarily serotonergic side effects such as nausea and vomiting. A phase IIb trial in moderate to moderately severe strokes completed enrollment in June 2004.

Original languageEnglish (US)
Pages (from-to)119-120
Number of pages2
JournalCurrent Drug Targets: CNS and Neurological Disorders
Volume4
Issue number2
DOIs
StatePublished - Apr 2005

Fingerprint

Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Brain Ischemia
Nausea
Vomiting
Glutamic Acid
Stroke
Clinical Trials
Wounds and Injuries
Pharmaceutical Preparations

Keywords

  • Acute stroke treatment
  • Infarct
  • Ischemia
  • Neuroprotectant
  • Neuroprotection
  • Repinotan

ASJC Scopus subject areas

  • Pharmacology
  • Neuroscience(all)

Cite this

Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke. / Lutsep, Helmi.

In: Current Drug Targets: CNS and Neurological Disorders, Vol. 4, No. 2, 04.2005, p. 119-120.

Research output: Contribution to journalArticle

@article{c850a5d6e2984656b08ed11ed5e88c70,
title = "Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke",
abstract = "Serotonin agonists can reduce glutamate-induced excitotoxicity in cerebral ischemia. The potent 5-HT1A agonist BAY × 3702, or repinotan, has reduced cortical infarct volume in pre-clinical models even when given 5 hours after injury. Early clinical trials showed that the drug was safe, and displayed primarily serotonergic side effects such as nausea and vomiting. A phase IIb trial in moderate to moderately severe strokes completed enrollment in June 2004.",
keywords = "Acute stroke treatment, Infarct, Ischemia, Neuroprotectant, Neuroprotection, Repinotan",
author = "Helmi Lutsep",
year = "2005",
month = "4",
doi = "10.2174/1568007053544165",
language = "English (US)",
volume = "4",
pages = "119--120",
journal = "CNS and Neurological Disorders - Drug Targets",
issn = "1871-5273",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke

AU - Lutsep, Helmi

PY - 2005/4

Y1 - 2005/4

N2 - Serotonin agonists can reduce glutamate-induced excitotoxicity in cerebral ischemia. The potent 5-HT1A agonist BAY × 3702, or repinotan, has reduced cortical infarct volume in pre-clinical models even when given 5 hours after injury. Early clinical trials showed that the drug was safe, and displayed primarily serotonergic side effects such as nausea and vomiting. A phase IIb trial in moderate to moderately severe strokes completed enrollment in June 2004.

AB - Serotonin agonists can reduce glutamate-induced excitotoxicity in cerebral ischemia. The potent 5-HT1A agonist BAY × 3702, or repinotan, has reduced cortical infarct volume in pre-clinical models even when given 5 hours after injury. Early clinical trials showed that the drug was safe, and displayed primarily serotonergic side effects such as nausea and vomiting. A phase IIb trial in moderate to moderately severe strokes completed enrollment in June 2004.

KW - Acute stroke treatment

KW - Infarct

KW - Ischemia

KW - Neuroprotectant

KW - Neuroprotection

KW - Repinotan

UR - http://www.scopus.com/inward/record.url?scp=18044387563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18044387563&partnerID=8YFLogxK

U2 - 10.2174/1568007053544165

DO - 10.2174/1568007053544165

M3 - Article

C2 - 15857296

AN - SCOPUS:18044387563

VL - 4

SP - 119

EP - 120

JO - CNS and Neurological Disorders - Drug Targets

JF - CNS and Neurological Disorders - Drug Targets

SN - 1871-5273

IS - 2

ER -